Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
BMC
Neuroscience
Alzheimer's Disease
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
April 17, 2021
2021
DOI: 10.1186/s13195-021-00813-8
The Lancet
Infectious Disease
COVID-19
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
April 4, 2021
2021
DOI: 10.1016/S0140-6736(21)00461-X
The New England Journal of Medicine
Infectious Disease
COVID-19
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
February 25, 2021
2021
DOI: 10.1056/NEJMoa2100433
JAMA
Sepsis
Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial
February 23, 2021
2021
DOI: 10.1001/jama.2020.24505
JAMA Oncology
Oncology
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis
January 6, 2021
2021
DOI: 10.1001/jamaoncol.2015.6113
JAMA
Infectious Disease
COVID-19
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
September 2, 2020
2020
DOI: 10.1001/jama.2020.17022
The Lancet
Oncology
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
September 1, 2020
2020
DOI: 10.1016/S1470-2045(20)30321-1
ATS
Infectious Disease
COVID-19
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design
April 8, 2020
2020
DOI: 10.1513/AnnalsATS.202003-192SD
No results found.
There are no results with this criteria. Try changing your search.